Expansions

Jan 31, 2007
By PharmTech Editors
Ravensburg, Germany (Jan. 23)Vetter Pharma-Fertigung GmbH & Co. KG (www.vetter-pharma.com) received a manufacturing license for its new Ravensburg Vetter South plant. The automated production facility will provide single-chamber cartridges, dual-chamber syringes and cartridges, and fill liquid and lyophilized vials.

Wilmington, DE (Jan. 22)AstraZeneca (www.astrazeneca.com) will invest $100 million to expand its Waltham, Massachusetts facility by 132,000 ft2 to boost infectious-disease and cancer research. The expanded facility will accommodate roughly 100 additional researchers who will join the more than 400 current discovery employees.

St. Petersburg, FL (Jan. 17)Dermazone Solutions, Inc. (www.dermazonesolutions.com) introduced its new contract-manufacturing division, dermaCM (www.dermacm.com), and its topical pharmaceutical and cosmeceutical manufacturing and development facility. dermaCM will offer formulation, private labeling, manufacturing, packaging, and fulfillment services.

Shanghai, China (Jan. 16)WuXi PharmaTech (www.pharmatechs.com), a provider of pharmaceutical research and development outsourcing services, began moving the first group of scientists to its new Tianjin research facility. The new facility complements the Shanghai research campus with 130,000 ft2 of laboratory space.

Leverkusen, Germany (Jan. 16)Lanxess (www.lanxess.com) earmarked EUR 30 million to develop its fine-chemicals subsidiary Saltigo (www.saltigo.com). The money will go toward modernizing Saltigo's plant and introducing new worktime models. A EUR 10-million multipurpose facility also is under construction.

Morton Grove, IL (Jan. 6)Regis Technologies, Inc. (www.registech.com) added supercritical fluid chromatography (SFC) to its separations services and will offer GMP separations starting April 1, 2007. Regis will offer SFC as a stand-alone service or in concert with its GMP manufacturing.

Parsippany, NJ (Jan. 3)DSM Pharmaceuticals (www.dsmpharmaceuticals.com) completed an expansion to its sterile parenteral manufacturing facility in Greenville, North Carolina. The expansion adds a clinical-trial materials manufacturing suite that is capable of manufacturing large- and small-molecule liquid and lyophilized products.